3D-PharmXchange celebrates its 10th anniversary on February 1st this year.  It is a Dutch consultancy firm focusing on the development of (bio-) pharmaceuticals together with the biotech and pharmaceutical industries. Since its inception in 2010, the company has supported a wide range of programs and is proud to continue to play a key role in bringing a number of cutting edge innovations forward. Currently, the company is involved in CMC leadership for bringing new gene therapies to patients in ALS with full ownership of the development and program management. In addition, two of Europe’s biggest biotech companies are working together with 3D-PharmXchange in project leadership and various core team roles within its expert disciplines. 3D-PharmXchange has offices in Tilburg and on Pivot Park (Oss).

“ Moving forward, our goal is to deepen our expertise in all four functional areas by rapidly expanding the team. “ said Ronald van der Geest, one of 3D-PharmXchange managing partner. “We have made an excellent progress since last year and will continue to restructure the company to encompass this growth through functional leadership; further strengthening of our cross-functional knowledge exchange, making sure our clients do not only benefit from a single person’s expertise, but tap into the growing knowledge-based available in our company.”

Our multidisciplinary team consists of CMC (small molecules, biologicals), non-clinical , clinical and regulatory experts to fully support clients with their development program or on a need-basis.  For more information, please visit our website https://www.3d-pxc.com/ or send us an email to: info@3d-pxc.com